• 제목/요약/키워드: Valve prosthesis

검색결과 160건 처리시간 0.188초

복부 대동맥류의 임상적 경험 (Clinical Experience of Abdominal Aortic Aneurysm)

  • 구본일;오상준
    • Journal of Chest Surgery
    • /
    • 제28권3호
    • /
    • pp.263-267
    • /
    • 1995
  • A total and consecutive 87 patients underwent aortic valve replacement[AVR with the St. Jude Medical prosthesis between 1984 and 1993. Age ranged from 14 to 66 years[mean:38.6$\pm$ 14.0 years .Twenty-one patients [24.1% had undergone previous valve replacement. There were 8 early deaths with an operative mortality rate of 9.2% [7.6% for primary AVR and 14.3 % for re-replacement AVR . Seventy-nine early survivors were,followed for a total of 309.1 patient-years[mean:3.9$\pm$ 2.5 years . A late mortality rate was 5.1% [4 patients or a linearized incidence of 1.294 %/patient-year. All were anticoagulated with coumadin to maintain the international normal ized ratio[INR between 1.5 and 2.5. One patient experienced thromboembolism[0.324%/patient-year , and none did bleeding. Endocarditis occurred in one[0.324%/patient-year . Paravalvular leak was the most frequent complication and was experienced by 8 patients[2.588%/patient-year , and 5 of them required re-replacement AVR[1.618 %/patient year of reoperation rate . There was no structural failure of the prosthesis. Actuarial survival including operative death was 83.9%$\pm$ 4.6% at 10 years.The actuarial estimates of freedom from thromboembolism and of freedom from late death and all complications were 95.1% $\pm$ 4.8 % and 81.4% $\pm$ 6.1%, respectively, at 10 years. These clinical results suggest that less intensive anticoagulation may be allowed for patients of AVR with the St. Jude Medical valve with low incidences of both thromboembolic and bleeding complications.

  • PDF

St. Jude Medical 판을 이용한 심판막 치환술의 성적 (A 6 Year Experience with the St. Jude Medical Cardiac Valve Prosthesis)

  • 조광현
    • Journal of Chest Surgery
    • /
    • 제25권3호
    • /
    • pp.296-306
    • /
    • 1992
  • A 6 year experience with the bileaflet St. Jude Medical valve is reported. Between Feb. 1986 and Dec. 1992, 68 patients received 87 such valves[36 mitral, 13 aortic, and 19 double mitral-aortic valve replacements]. The results are summarized as follows 1. There were 35 male and 33 female patients ranging in age from 17 to 55 years the mean age of 35.3 $\pm$ 9.7 years. 2. The mean aortic clamp time[ACT] of the MVR, AVR and DVR groups were 91.5$\pm$16.4, 117.2$\pm$28.7 and 165.5$\pm$24.1 minutes. The mean total bypass time [TBT] of the MVR, AVR and DVR groups were 112.8$\pm$19.5, 134.7$\pm$31.4 and 192.2$\pm$28.5 minutes. 3. Eighty seven valves were used [55 mitral site, 32 aortic site]. 31mm[20], 33mm[15], 29mm[15], 27mm[2], 25mm[2] and 35mm[1] were used in mitral site and 23mm[13], 21mm[8], 19mm[7] and 25mm[4] were used in the aortic site. In the DVR, there were valve combinations such as 4 cases of M[29mm]-A[19mm], 4 of M[31mm]-A[23mm], 3 of M[33mm]-A[23mm] and others. 4. Preoperative NYHA functional classes were II [3 cases], III [46 cases], IV[19 cases] and improved to I [52 cases] and Il [13 cases] postoperatively. 5 Early postoperative complications were occurred in 15 cases[2Z.l%] and there were LOS in 5 cases[7.4%], arrythmia [3 cases], wound infection [2 cases], hepatitis [2 cases], sudden cardiac arrest [2 cases] and postoperative bleeding [1 case]. The early hospital death was occurred in 3 cases[4.4%] with LOS [1 case] and sudden cardiac arrest [2 cases]. 6. Mean follow-up time of survival cases[65 cases] was 31.3$\pm$21.9 months and the total follow-up time was 169.8 patient-years. Late postoperative complications were occurred in 4 cases[2 thromboembolism, 1 paravalvular leak, 1 thromboembolism br paravalvular leak, 1 valve endocarditis] with the occurrence rate as 2.35% per patient-years. Reoperation was performed in 2 cases [1 paravalvular leak, 1 left atrial thrombus] and there was one [1.5%] late valve related death. Therefore the 6 year complication free rate was 90.6% and 6 year actuarial survival rate was 98.3$\pm$1.7%. On the basis of this experience and the results, SJMvalve appears to be one of the best performing mechanical prosthesis currently available, in terms of both hemodynamics and lower complications with warfarin antioagulation.

  • PDF

Early Outcomes of Sutureless Aortic Valves

  • Hanedan, Muhammet Onur;Mataraci, Ilker;Yuruk, Mehmet Ali;Ozer, Tanil;Sayar, Ufuk;Arslan, Ali Kemal;Ziyrek, Ugur;Yucel, Murat
    • Journal of Chest Surgery
    • /
    • 제49권3호
    • /
    • pp.165-170
    • /
    • 2016
  • Background: In elderly high-risk surgical patients, sutureless aortic valve replacement (AVR) should be an alternative to standard AVR. The potential advantages of sutureless aortic prostheses include reducing cross-clamping and cardiopulmonary bypass (CPB) time and facilitating minimally invasive surgery and complex cardiac interventions, while maintaining satisfactory hemodynamic outcomes and low rates of paravalvular leakage. The current study reports our single-center experience regarding the early outcomes of sutureless aortic valve implantation. Methods: Between October 2012 and June 2015, 65 patients scheduled for surgical valve replacement with symptomatic aortic valve disease and New York Heart Association function of class II or higher were included to this study. Perceval S (Sorin Biomedica Cardio Srl, Sallugia, Italy) and Edwards Intuity (Edwards Lifesciences, Irvine, CA, USA) valves were used. Results: The mean age of the patients was $71.15{\pm}8.60years$. Forty-four patients (67.7%) were female. The average preoperative left ventricular ejection fraction was $56.9{\pm}9.93$. The CPB time was $96.51{\pm}41.27minutes$ and the cross-clamping time was $60.85{\pm}27.08minutes$. The intubation time was $8.95{\pm}4.19hours$, and the intensive care unit and hospital stays were $2.89{\pm}1.42days$ and $7.86{\pm}1.42days$, respectively. The mean quantity of drainage from chest tubes was $407.69{\pm}149.28mL$. The hospital mortality rate was 3.1%. A total of five patients (7.69%) died during follow-up. The mean follow-up time was $687.24{\pm}24.76days$. The one-year survival rate was over 90%. Conclusion: In the last few years, several models of valvular sutureless bioprostheses have been developed. The present study evaluating the single-center early outcomes of sutureless aortic valve implantation presents the results of an innovative surgical technique, finding that it resulted in appropriate hemodynamic conditions with acceptable ischemic time.

삼첨판막 심내막염 (Tricuspid Valve Endocarditis)

  • 문광덕;김대영
    • Journal of Chest Surgery
    • /
    • 제29권4호
    • /
    • pp.440-443
    • /
    • 1996
  • 삼첨 판막 심내막염은 감수성이 있는 항생제에 효과적으로 치료될 수 있다. 그러나 패혈증이 지속되거 나, 중증의 심부전, 다발성 폐 색전증 그리고 실 초음파상 증식증 (vegetation)이 있는 경우는 수술이 필요 하다. . 19세횝 남자환자가 감염성심내막염으로 입원하였다. 환자는 9년전에 perimembranous type의 VSD로 수술받은 병 력 이 있다. 심초음파상 삼첨판의 전엽부에 커다란 증식증의 소견이 보였고,과거에 VSD를 봉합했던 부위에 누 출 (leakage)을 통한 좌우단락이 관찰되었다. 항생제치료와 함께 인공판막치 환술을 시행하였다. St. Jude Medical 양엽판막 (size 33 mm으로 삼첨 판막 대 치술을 시 행하였고 잔여 VSD는 단순봉합으 로 폐쇄하였다. 술후 시행한 심초음파검사에서 치환된 삼첨 판막의 기능은 좋았고, 증식증과 좌우단락의 소견은 보이지 않았다. 환자는 합병증없이 술후 25일째에 퇴원하였다. 저자들이 경험한 본 증례는 잔여 VSD로 인해 생긴 감염성심내막염을 초기에 적극적인 수술을 시행 하여 좋은결과를 얻었음을 보여준다. 이 에 문헌고찰과 더불어 보고하는 바이다.

  • PDF

Multiple Embolic Aortic Valve Endocarditis with Small Patent Ductus Arteriosus in Adult

  • Kim, Seon Hee;Song, Seunghwan;Kim, Min Su;Kim, Sang-Pil;Choi, Jung Hyun
    • Journal of Chest Surgery
    • /
    • 제47권2호
    • /
    • pp.137-140
    • /
    • 2014
  • A 50-year-old female was admitted to Pusan National University Hospital with complaints of fatigue and sweating. Echocardiography showed a small patent ductus arteriosus (PDA) and highly mobile vegetations on the aortic valve. Emergency operation was performed due to the high risk of embolization and severe aortic regurgitation. When the pulmonary artery opened, we found unexpected fresh vegetation. The tissue of the PDA was fragile and infected. We successfully removed the infected tissue, closed the PDA with a patch, and replaced the aortic valve with a mechanical prosthesis.

심실중격결손과 동반한 다중판막 감염성 심내막염의 수술적 치료 (Surgical Treatment of Multivalvular Endocarditis with Ventricular Septal Defect)

  • 김선희;제형곤;이상권;김상필
    • Journal of Chest Surgery
    • /
    • 제43권4호
    • /
    • pp.417-420
    • /
    • 2010
  • 다중판막을 침범한 감염성 심내막염은 단일 심내막염에 비해 사망률이 높고 합병증의 발생이 빈번하여 일반적으로 조기수술이 권장된다. 저자들은 고열을 주소로 입원한 46세 환자에서 심초음파 검사로 폐동맥판막, 삼첨판막, 승모판막을 침범한 급성 심내막염 및 심실중격결손을 진단하였고, 항생제 치료에도 감염증이 악화되어 응급수술을 시행하였다. 비교적 드문 증례를 성공적으로 치료하였기에 문헌고찰과 함께 보고하는 바이다.

혈전증에 의한 급성 인공판막기능부전의 수술 1례 (Surgical Treatment of Acute Prosthetic Valve Fai lure by Thrombosis -One Case Report-)

  • 이재덕;이서원;이재원;신제균
    • Journal of Chest Surgery
    • /
    • 제29권6호
    • /
    • pp.651-654
    • /
    • 1996
  • 최근에 본원에서 혈전증에 의한 급성 인공판막기능부전 1례를 치험하였기에 보고한다. 환자는39세 남자로서 내원 3일전부터 호흡곤란과 기 좌호흡을 호소하였다. 과거력 상 인공판막대치술 후 의사의 충고에도 불구하고 최근 4개월 동안 항응고제를 복용하지 않았다. 심초음파검사상 인공판막 판엽의 움직임에 제한이 있었다. 우리는 응급으로 혈전제거술과 인공판막 재치환술을 시행하였다. 수술 후 환자는 특별한 합병증없이 추적 관찰중에 있다.

  • PDF

Enoxaparin as an Anticoagulant in a Multipara with a Mechanical Mitral Valve: A Case Report

  • Yo Seb Lee;Jun Seok Kim
    • Journal of Chest Surgery
    • /
    • 제56권6호
    • /
    • pp.452-455
    • /
    • 2023
  • Patients who have undergone mechanical valve replacement require anticoagulation therapy with warfarin to prevent thromboembolism. However, administering warfarin to pregnant patients increases their risk of warfarin embryopathy or central nervous system disorders. Consequently, safer alternatives, such as heparin or low-molecular-weight heparin injection, are substituted for warfarin. However, limited research has been conducted on this subject, with no large-scale studies and particularly few investigations involving multiparous patients. A patient who had previously undergone mechanical mitral valve replacement for atrial septal defect and mitral stenosis received anticoagulant therapy with enoxaparin during 2 pregnancies. Upon confirmation of pregnancy, warfarin was replaced with subcutaneously injected enoxaparin with a dosage of 1 mg/kg at 12-hour intervals. The enoxaparin dosage was controlled using an anti-factor Xa assay, with a target range of 0.3-0.7 IU/mL. Intravenous heparin injections were administered starting 3 days prior to the expected delivery date and were continued until delivery, after which warfarin was resumed. No complications were observed during the deliveries.

협소한 대동맥판륜 환자에서의 대동맥판막 치환술; 대동맥판륜 확장술군과 환자-인공판막 부조화군의 비교 (Small Aortic Annulus in Aortic Valve Replacement; Comparison between Aortic Annular Enlargement Group and Patient-prosthesis Mismatch Group)

  • 김재현;오삼세;이길수;신성호;백만종;나찬영
    • Journal of Chest Surgery
    • /
    • 제40권3호
    • /
    • pp.200-208
    • /
    • 2007
  • 배경: 대동맥판막 치환술 후 발생하는 환자-인공판막 부조화(patient-prosthesis mismatch, PPM)가 환자의 경과에 어떠한 영향을 주는가에 대해서는 아직 논란의 여지가 있다. 이 연구는 대동맥판막 치환술 후 PPM이 발생한 환자군과 PPM을 예방하기 위해 대동맥판륜 확장술을 시행한 환자군 간의 수술 결과와 경과를 비교해 보았다. 대상 및 방법: 1996년 1월부터 2006년 2월까지 stent가 있는 조직판막 혹은 기계판막을 이용하여 대동맥판막 치환술을 시행 받은 627명의 성인 환자를 연구대상으로 하였다. 치환된 대동맥판막의 indexed effective orifice area (iEOA)가 $0.85cm^2/m^2$ 이하인 경우를 PPM으로 정의 하였고 $0.65cm^2/m^2$ 이하는 심한 PPM으로 정의하였다 PPM은 103명(16.4%, PPM군)에서 발생하였고 심한 PPM은 11명(1.8%, SPPM군)에서 발생하였다. 동일한 연구 기간 동안 대동맥판륜 확장술을 시행 받은 환자(Annular Enlargement군, AE)는 모두 21명이었다. 결과: AE군의 평균 iEOA는 PPM군보다 더 컸다($0.95\;vs.\;0.76cm^2/m^2,\;p=0.00$). AE군은 PPM군보다 심폐바이패스 시간, 심장허혈 시간 및 수술 시간이 더 길었으며 수술 사망률이 더 높은 경향을 보였다(14.3% vs. 2.9%, p=0.06). 술 후 가장 최근에 시행한 심초음파 검사에서 SPPM군은 대동맥판막 판구 압력차(최고/평균)가 AE군보다 더 높게 나타났으며(72/45 mmHg vs. 38/25 mmHg, p=0.02/0.06), 대동맥판막 관련 문제(대동맥판막 재치환술 혹은 심한 대동맥판막 협착)가 더 많이 발생하였다(45.5% vs. 9.5%, p=0.03). 또한 대동맥판막 관련 문제가 발생한 환자들에서는 좌심실 심근량 감축(regression)을 관찰할 수 없었다. 결론: 협소한 대동맥판륜을 가진 환자에서 대동맥판륜 확장술의 시행여부는 대동맥판륜 확장술 자체의 위험도와 환자 상태 및 동반 질환 등을 함께 고려하여 신중히 결정하여야 한다. 하지만 대동맥판막 치환술 후 심한 PPM이 예상되는 환자에서는 대동맥판륜 확장술이 대안으로 이용될 수 있다.

감염성 심내막염의 외과적 치료 (Surgical Treatment of Native Valve Endocarditis)

  • 김애중;김민호;김공수
    • Journal of Chest Surgery
    • /
    • 제28권9호
    • /
    • pp.822-828
    • /
    • 1995
  • This paper reports 15 native valve endocarditis cases had surgical operation in the past 10 years at the department of Cardiovascular and Thoracic Surgery, Chonbuk National University Hospital. In this study, 10 cases out of 15 were in class I or II by the New York Heart Association functional classification. None of the cases had a history of taking addictive drugs. Five cases were congenital heart disease, three cases were rheumatic heart disease and two cases were degenerative heart disease. Thus 10 cases had the underlying disease. All cases had antibiotics treatment for 3 to 6 weeks before operation. In the culture test, only four cases were positive in the blood culture and one case was positive in the excised valve culture. Organisms on blood and valve culture were Streptococcus epidermis, Streptococcus viridans, Staphylococcus aureus and Staphylococcus epidermidis. In the 10 cases without ventricular septal defect, the aortic valve was involved in four, mitral in four, both in two and involved valves in the 5 cases with ventricular septal defect were tricuspid in three, pulmonic in two. Eight cases had operation because they showed moderate congestive heart failure due to valvular insufficiency and vegetation with or without embolism. Seven cases had operation because they showed persistent or progressive congestive heart failure and/or uncontrolled infection. Five cases with ventricular septal defect underwent the closure of ventricular septal defect, vegetectomy and leaflet excision of the affected valves without valve replacement. In the cases without ventricular septal defect, the affected valves were replaced with St. Jude mechanical prosthesis. Postoperative complications were recurrent endocarditis in two, embolism in one, allergic vasculitis in two, spleen rupture in one and postpericardiotomy syndrome in one. At the first postoperative day, one case died of cerebral embolism. At the 11th postoperative month, one case died of recurrent endocarditis and paravalvular leakage in spite of a couple of aortic valve replacement. In the survived cases[13 cases in this study , all cases but one became class I or II by the New York Heart Association functional classification.

  • PDF